Get the Stockscreener App
200.36
1.99%
-3.46
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Ligand Pharmaceuticals Inc stock is traded at $200.36, with a volume of 81,032.
It is down -1.99% in the last 24 hours and up +1.21% over the past month.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
See More
Previous Close:
$203.82
Open:
$203.87
24h Volume:
81,032
Relative Volume:
0.37
Market Cap:
$3.93B
Revenue:
$152.42M
Net Income/Loss:
$45.24M
P/E Ratio:
79.82
EPS:
2.51
Net Cash Flow:
$6.97M
1W Performance:
+3.52%
1M Performance:
+1.21%
6M Performance:
+46.66%
1Y Performance:
+73.14%
1-Day Range:
$199.32
$205.87
1-Week Range:
$189.26
$207.06
52-Week Range:
$93.58
$212.49
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Name
Ligand Pharmaceuticals Inc
Sector
Industry
Phone
858-550-7500
Address
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Compare LGND with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
199.76 | 4.01B | 152.42M | 45.24M | 6.97M | 2.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.63 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.34 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
811.57 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.84 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Citigroup | Buy |
| Apr-10-25 | Initiated | Stifel | Buy |
| Oct-03-24 | Initiated | Oppenheimer | Outperform |
| Jul-30-24 | Initiated | RBC Capital Mkts | Outperform |
| Apr-14-21 | Resumed | Stephens | Overweight |
| Feb-04-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-06-20 | Initiated | Barclays | Overweight |
| Mar-24-20 | Downgrade | Argus | Buy → Hold |
| Mar-10-20 | Initiated | Guggenheim | Neutral |
| Feb-06-20 | Initiated | The Benchmark Company | Buy |
| Sep-19-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-03-19 | Reiterated | H.C. Wainwright | Buy |
| Mar-06-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-18 | Upgrade | ROTH Capital | Neutral → Buy |
| Oct-02-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-11-18 | Reiterated | Argus | Buy |
| Aug-17-18 | Initiated | Goldman | Neutral |
| Aug-08-18 | Downgrade | ROTH Capital | Buy → Neutral |
| Jun-21-18 | Initiated | Argus | Buy |
| Dec-27-17 | Reiterated | H.C. Wainwright | Buy |
| Sep-05-17 | Resumed | H.C. Wainwright | Buy |
| Oct-05-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-16 | Downgrade | Deutsche Bank | Hold → Sell |
| Mar-11-16 | Initiated | Sidoti | Buy |
| Mar-03-16 | Initiated | H.C. Wainwright | Buy |
View All
Ligand Pharmaceuticals Inc Stock (LGND) Latest News
Massachusetts Financial Services Co. MA Buys 202,103 Shares of Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Stephens Investment Management Group LLC Sells 50,271 Shares of Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
SG Americas Securities LLC Has $2.08 Million Stock Position in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Could Be 37% Below Their Intrinsic Value Estimate - Yahoo Finance UK
Travere, Ligand Hammered On A Surprise Delay For Their Linchpin Drug - Investor's Business Daily
Ligand Pharmaceuticals stock slides as FDA pushes back Travere’s Filspari decision to April 13 - TechStock²
Ligand Pharmaceuticals (NASDAQ:LGND) Shares Gap DownShould You Sell? - MarketBeat
Patterns Watch: Can Ligand Pharmaceuticals Incorporated stock continue upward trendJuly 2025 Breakouts & Safe Capital Growth Plans - Bộ Nội Vụ
Published on: 2026-01-13 22:28:13 - Bộ Nội Vụ
Ligand Pharmaceuticals (LGND) Stock Analysis: Riding on a Wave of Revenue Growth and Analyst Optimism - DirectorsTalk Interviews
Gamble on Huge Gains with These 3 Best Biotech Stocks to Buy for 2026 - Yahoo Finance
Can Ligand Pharmaceuticals Incorporated stock rebound after recent weaknessJuly 2025 Fed Impact & Safe Entry Zone Tips - Улправда
Will Ligand Pharmaceuticals Incorporated stock remain a Wall Street favoriteTrade Risk Assessment & Daily Risk Controlled Trade Plans - Улправда
What technical signals suggest for Ligand Pharmaceuticals Incorporated stockJuly 2025 EndofMonth & High Win Rate Trade Tips - Улправда
Is Ligand Pharmaceuticals Incorporated stock attractive for hedge fundsQuarterly Trade Report & Entry Point Confirmation Signals - ulpravda.ru
Is Ligand Pharmaceuticals Incorporated stock a top momentum playExit Point & Free Long-Term Investment Growth Plans - Улправда
Is Ligand Pharmaceuticals Incorporated (LGDN) stock positioned for digital growth eraMarket Performance Summary & Weekly High Return Opportunities - Улправда
Is Ligand Pharmaceuticals Incorporated stock positioned well for digital economyJuly 2025 Snapshot & Weekly Setup with High ROI Potential - Улправда
Risk Recap: How Ligand Pharmaceuticals Incorporated stock reacts to oil pricesMarket Trend Review & Verified Stock Trade Ideas - Улправда
Ligand Pharmaceuticals director Kozarich sells $88,532 in stock By Investing.com - Investing.com South Africa
Book value per share of Ligand Pharmaceuticals Incorporated – OTC:LGNYZ - TradingView — Track All Markets
Ligand Pharmaceuticals director Kozarich sells $88,532 in stock - Investing.com
Allspring Global Investments Holdings LLC Buys 32,379 Shares of Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Moody Aldrich Partners LLC Buys Shares of 25,884 Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Calamos Advisors LLC Grows Stake in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Tangible book value per share of Ligand Pharmaceuticals Incorporated – OTC:LGNYZ - TradingView — Track All Markets
Ligand Pharmaceuticals Earnings Notes - Trefis
Book value per share of Ligand Pharmaceuticals Incorporated – OTC:LGNZZ - TradingView — Track All Markets
Loss Report: How Ligand Pharmaceuticals Incorporated stock reacts to bond yieldsTrade Analysis Report & Daily Market Momentum Tracking - moha.gov.vn
Ligand Pharmaceuticals Incorporated $LGND Position Trimmed by Rice Hall James & Associates LLC - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) Releases FY 2025 Earnings Guidance - MarketBeat
Benefactor John Kozarich visits BC Engineering Department - bc.edu
Ligand Pharmaceuticals (LGND) Price Target Increased by 24.57% to 232.69 - MSN
Ligand Pharmaceuticals IncorporatedEquity Right (LGNDZ) Price Target Increased by 23.15% to 0.01 - Nasdaq
Ligand Pharmaceuticals Incorporated $LGND Stock Holdings Increased by Congress Asset Management Co. - MarketBeat
Published on: 2025-12-20 22:34:37 - Улправда
Will Ligand Pharmaceuticals Incorporated stock continue upward momentum2025 Earnings Impact & Community Consensus Stock Picks - Улправда
How sustainable is Ligand Pharmaceuticals Incorporated stock dividend payoutJuly 2025 Action & Low Volatility Stock Recommendations - Улправда
Octavio Espinoza At Ligand Pharmaceuticals Capitalizes: Options Exercised, Resulting In $308K - Benzinga
Will Ligand Pharmaceuticals Incorporated stock deliver better than expected guidance2025 Growth vs Value & Weekly High Conviction Ideas - Улправда
[Form 4] LIGAND PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
Ligand Pharmaceuticals backs Athira Pharmas 90 million funding round - Traders Union
Published on: 2025-12-19 00:15:21 - Улправда
Why Ligand Pharmaceuticals Incorporated stock could outperform in 2025July 2025 Technicals & Proven Capital Preservation Methods - Улправда
Gains Recap: Will Ligand Pharmaceuticals Incorporated stock continue upward momentum2025 Trading Volume Trends & Safe Capital Investment Plans - Улправда
Woodstock Corp Sells 9,472 Shares of Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
FY2026 Earnings Forecast for LGND Issued By Zacks Small Cap - MarketBeat
Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue? - Yahoo Finance
LIGAND PHARMACEUTICALS CFO Sells Shares - TradingView — Track All Markets
Ligand Pharmaceuticals (NASDAQ:LGND) CFO Sells $339,711.24 in Stock - MarketBeat
Ligand Pharmaceuticals Inc Stock (LGND) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.38%
1.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):